Dynamic Pharmaceuticals Invesco ETF (PJP)

$76.40 0.42 (0.55%)

20:00 EDT PJP Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 2.64M

PE Ratio -

EPS -

Volume (Avg. Vol.) 3,586

Day's Range $76.40 - $76.90

52-Week Range $67.75 - $80.65

Dividend & Yield $0.80 (1.05%)

PJP Stock Predictions, Articles, and Dynamic Pharmaceuticals Invesco ETF News

From the Web

Want to Invest in Pharmaceutical Stocks but Don't Know How? Try This ETF.

From The Motley Fool May 18, 2023

Simplify your exposure to an ever-changing prescription drug market with this rules-based fund.

Wave of Solid Q3 Earnings Push Pharma ETFs Higher

From Talk Markets Nov 9, 2021

The slew of Q3 results has led to smooth trading in pharma ETFs over the past month.

Will Pfizer ETFs Soar on FDA's COVID-19 Vaccine Booster Approval?

From Talk Markets Sep 24, 2021

Investors have one more reason to cheer the COVID-19 vaccine update as the FDA has approved emergency use of a booster dose of the Pfizer Inc. and BioNTech SE COVID-19 vaccine.

3 Under the Radar Pharmaceutical Stocks to Add to Your Watchlist

From StockNews.com Aug 25, 2021

The pharmaceutical industry is expected to attract significant investor attention in the coming months as the demand for vaccines and therapies continues to soar with the resurgence of COVID-19 cases globally. This demand, coupled with an astonishing level of scientific advances for treating several critical diseases, will likely bolster the industry’s growth. Therefore, we believe that under-the-radar pharmaceutical stocks Catalyst Pharmaceuticals (CPRX), Kamada (KMDA), and Opiant Pharmaceuticals (OPNT) could deliver excellent returns in the near term. Let’s discuss.

Merck vs. Sanofi: Which Pharmaceutical Stock is a Better Buy?

From StockNews.com Jun 30, 2021

While the pharmaceutical industry’s upside potential based on its role in saving many lives from the deadly coronavirus virus is gradually diminishing, the continuing efforts of pharma companies in finding cures for critical diseases should keep driving the industry’s growth, with rising demand from an aging population. Despite huge industry competition, recent developments made by Merck (MRK) and Sanofi (SNY) are likely to boost their growth substantially. But let’s find out which of these stocks is a better buy now.

Pharma ETFs in Focus Post Q1 Earnings

From Talk Markets May 12, 2021

The slew of Q1 results has led to mixed trading in pharma ETFs over the past month. Here are those in detail.

ADVERTISEMENT